GlassScriptPhysician profile
Aidan R Raney
NPI 1962631101
$112,718.96
in general payments reported to CMS, 2019-2025
46 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,887 · 2021: $30K · 2022: $14K · 2023: $18K · 2024: $18K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Food and Beverage: $4,626 · Travel and Lodging: $3,421 · Long Term Medical Supply Or Device Loan: $282 · Grant: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,887.50 |
| Food and Beverage | $4,625.59 |
| Travel and Lodging | $3,420.77 |
| Long Term Medical Supply Or Device Loan | $281.66 |
| Grant | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $82,532.54 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Abbott Laboratories | $8,876.82 | 2019-2025 | Portico, Mitraclip, Triclip |
| Abiomed | $5,033.40 | 2019-2025 | Impella |
| Cardiovascular Systems INC. | $4,478.29 | 2019-2021 | |
| Opsens INC. | $2,554.36 | 2022 | |
| W. L. Gore & Associates, INC. | $1,900.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,163.48 | 2019-2025 | |
| Medtronic, INC. | $735.53 | 2021-2025 | Corevalve Evolut R, Linq II |
| Shockwave Medical, INC | $657.74 | 2020-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $552.20 | 2019-2025 | Avvigo Guidance System, Bodyguardian, Watchman Flx |
| Pfizer INC. | $405.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $391.98 | 2019-2023 | Xarelto |
| Acutus Medical, INC. | $353.64 | 2020-2021 | |
| Amgen INC. | $308.78 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $308.02 | 2022-2025 | Camzyos, Eliquis |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aidan Raney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.